Algeta Recruits Bayer To Deliver Prostate Cancer Drug Alpharadin To Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Big Pharma still hot for castration-resistant prostate cancer drugs, despite Phase III burns in the past.
You may also be interested in...
Algeta, Aspiring For Solo Success, Draws Bayer Bid After Xofigo Launch
The Norwegian biotech is keen to show it is not a one-trick pony, but its future might lie in the embrace of its big pharma partner Bayer.
Bayer Bids $2.4 Billion To Acquire Norwegian Biotech Partner Algeta
Bayer would gain full control of the potential blockbuster prostate cancer therapy, Xofigo, if successful.
Phase III Results For Bayer/Algeta's Alpharadin Hint Of Labeling Down The Line
In what's become a crowded field of drugs for advanced prostate cancer, Algeta takes aim at symptomatic bone metastases.